Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHD3R8)

Drug Name

D-4476 Drug Info

Synonyms

CK1 inhibitor; D 4476

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Preclinical	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Casein kinase I alpha (CSNK1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BTX-A51	DMC8XHQ	Advanced solid tumour	2A00-2F9Z	Phase 1	[4]
US9096594, 3	DM8UOKE	N. A.	N. A.	Patented	[5]
IC261	DMXB95R	Pancreatic cancer	2C10	Preclinical	[6]
PMID24900428C14	DMU4BL2	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------

Drug(s) Targeting Casein kinase I delta (CSNK1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IC261	DMXB95R	Pancreatic cancer	2C10	Preclinical	[6]
PF-4800567	DM8P9ST	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[8]
PF-670462	DMTJBP9	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[9]
PMID24900428C14	DMU4BL2	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
2	Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization. Eur J Med Chem. 2012 Oct;56:30-8.
3	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
4	Clinical pipeline report, company report or official report of BioTheryX.
5	Kinase inhibitors and methods of use thereof. US9096594.
6	Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60.
7	Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64.
8	Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther. 2009 Aug;330(2):430-9.
9	Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218.